Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
P/B ratio for Sera Prognostics, Inc. (SERA)
P/B ratio as of 2023: 2.66
According to Sera Prognostics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.66. At the end of 2022 the company had a P/B ratio of 0.39.
P/B ratio history for Sera Prognostics, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.66 |
| 2022 | 0.39 |
| 2021 | 1.53 |
| 2020 | -2.91 |
| 2019 | -3.43 |